Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clomid in Men With Low Testosterone With and Without Prior Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01904734
Recruitment Status : Completed
First Posted : July 22, 2013
Last Update Posted : March 10, 2021
Sponsor:
Information provided by (Responsible Party):
Sherman M. Harman, Phoenix VA Health Care System

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study aims to explore whether men with low testosterone levels, due to altered brain regulation of male hormone function, who have been previously treated with testosterone, respond as well as men who have not been so treated to clomiphene citrate, an agent commonly used for female infertility that has been shown to improve male hormone secretion in some cases.

Condition or disease Intervention/treatment Phase
Hypogonadism, Male Drug: Clomiphene Phase 2

Detailed Description:
Clomiphene, an oral FDA-approved agent for female infertility has been shown to normalize testosterone levels in men with hypogonadotropic hypogonadism. It appears to be safe and well tolerated. This study will compare testosterone responses to clomiphene citrate in male veterans with hypothalamic hypogonadism naïve to treatment with responses of similar patients already receiving treatment with injectable or transdermal testosterone. This is an open-label, prospective, interventional trial to be conducted in an outpatient specialty care setting. We will randomize 64 hypogonadal male veterans evenly divided between naive and previous treatment and treat for 8 weeks with clomid, increasing the initial dose of 25 mg to 50 mg/day in those who fail to achieve target testosterone level (450 ng/dl) after the first 3 weeks. Endpoint measurements performed in the Phoenix VA Health Care System (PVAHCS) clinical laboratory will be total testosterone as well as bioavailable testosterone and sex hormone binding globulin. Total testosterone level at 8 weeks of treatment will be reported as the primary endpoint. Safety measures (CBC,liver functions, PSA) will be assessed at 8 weeks as well. This study will help serve as a guide for design of future studies of clomiphene in hypogonadal men.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Comparison of Clomiphene Citrate Responses in Men With Hypothalamic Hypogonadism naïve to, and Previously Treated With, Testosterone
Study Start Date : October 2012
Actual Primary Completion Date : October 31, 2018
Actual Study Completion Date : October 31, 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: No previous male hormone treatment
Clomiphene
 Drug: Clomiphene
Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
Other Names:
  • Clomid
  • Clomiphene citrate
Active Comparator: Previously treated with testosterone
Clomiphene
 Drug: Clomiphene
Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
Other Names:
  • Clomid
  • Clomiphene citrate


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Total serum testosterone [ Time Frame: at the end of 8 weeks of treatment ]
    laboratory measurement by standard immunometric method


Secondary Outcome Measures :
  1. Bioavailable testosterone [ Time Frame: at the end of 8 weeks of treatment ]
    Non-SHBG bound testosterone by ammonium sulfate precipitation method

  2. Serum sex hormone binding globulin (SHBG)level [ Time Frame: at the end of 8 weeks of treatment ]
    Laboratory measurement of SHBG by standard immunometric technique


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient or eligible for care at Phoenix VA Health Care System
  • Male ages 30-70 years
  • testosterone level below 250 ng/dl before treatment
  • able to provide informed written consent

Exclusion Criteria:

  • evidence of pituitary tumor >1mm by MRI or CAT scan
  • chronic illness (renal, cardiac, liver failure)
  • Prostate specific antigen (PSA) >4.0 ng/ml
  • history of prostate, breast, or testicular cancer
  • eye disease compromising vision (e.g. cataracts)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01904734


Locations
Layout table for location information
United States, Arizona
Phoenix VA Health Care System
Phoenix, Arizona, United States, 85012
Sponsors and Collaborators
Phoenix VA Health Care System
Investigators
Layout table for investigator information
Principal Investigator: Sherman M Harman, MD, PhD Phoenix VA Health Care System
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Sherman M. Harman, Chief, Endocrine Division, Dept. of Internal Medicine, Phoenix VA Health Care System
ClinicalTrials.gov Identifier: NCT01904734    
Other Study ID Numbers: VETSCLOMIDPHX
First Posted: July 22, 2013    Key Record Dates
Last Update Posted: March 10, 2021
Last Verified: March 2021
Keywords provided by Sherman M. Harman, Phoenix VA Health Care System:
testosterone
hypogonadism
pituitary
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypogonadism
Eunuchism
Gonadal Disorders
Endocrine System Diseases
Clomiphene
Enclomiphene
Zuclomiphene
Estrogen Antagonists
 Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators